Moderna (MRNA) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moderna (MRNA) has outperformed Royalty Pharma (RPRX) over the past year, gaining 605.6% versus a gain of 56.1%. Over five years, RPRX leads with a +46.4% price change compared with -39.2% for MRNA. Moderna is the larger company by market cap ($87.75 billion vs $32.93 billion), about 2.7 times the size, while Royalty Pharma is growing revenue faster (+5.1% vs -39.9%).
Royalty Pharma pays a dividend yielding 1.60%, while Moderna does not currently pay one. Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRNA | RPRX |
|---|---|---|
| Share price | $219.79 | $56.98 |
| Market cap | $87.75B | $32.93B |
| 1-day change | +11.57% | +1.37% |
| YTD return | +568.02% | +45.47% |
| 1-year return | +605.59% | +56.05% |
| 5-year return | -39.24% | +46.42% |
| P/E ratio (TTM) | — | 30.31 |
| Forward P/E | — | 9.94 |
| EPS (TTM) | $-7.98 | $1.88 |
| Dividend yield | 0.00% | 1.60% |
| Annual dividend | $0.00 | $0.91 |
| Revenue (latest FY) | $1.94B | $2.38B |
| Revenue growth (YoY) | -39.93% | +5.06% |
| Net income (latest FY) | $-2.82B | $770.95M |
| Gross margin | 55.35% | — |
| Operating margin | -158.13% | 65.58% |
| Net margin | -145.16% | 32.42% |
| 52-week high | $223.34 | $64.38 |
| 52-week low | $22.28 | $35.23 |
| Distance from 52-week high | -1.59% | -11.49% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -44.95% | +14.74% |
| Average volume | 17.95M | 2.92M |
| Shares outstanding | 399.24M | 445.28M |
| Employees | 4,700 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 2.7 times larger than Royalty Pharma by market value ($87.75B vs $32.93B).
- MRNA has outperformed RPRX by 549.5 percentage points over the past year.
- Royalty Pharma offers a meaningfully higher dividend yield (1.60% vs 0.00%).
- Royalty Pharma is more profitable, keeping 32.4 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Royalty Pharma grew revenue faster in its latest fiscal year (+5.06% vs -39.93%).
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
MRNA vs RPRX FAQ
Which is bigger, Moderna or Royalty Pharma?
Moderna (MRNA) is larger, with a market capitalization of $87.75B compared with $32.93B for Royalty Pharma (RPRX).
Which stock has performed better over the past year, MRNA or RPRX?
MRNA returned +605.59% over the past 12 months, compared with +56.05% for RPRX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Moderna or Royalty Pharma?
Royalty Pharma pays a dividend yielding 1.60%, while Moderna does not currently pay a regular dividend.
Are Moderna and Royalty Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Moderna and Biotechnology: Pharmaceutical Preparations for Royalty Pharma.